4TEEN4 Pharmaceuticals
Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%.
$7.77M Series A ·
Led by Brandenburg Kapital · Source: brandenburg-kapital.de
Latest round on record: Series B+, November 2025, amount undisclosed.
All 2 rounds ↓Signals
About 4TEEN4 Pharmaceuticals
Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S.
4TEEN4 Pharmaceuticals | 105 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com | |
| Series A | $7.77M | brandenburg-kapital.de |
Timeline
- X account created
- Website created
Founders and team
AB
Andreas Bergmann FounderMK
Mahir Karakas CTOCS
Christoph Springer COOJS
Joachim Struck CROKB
Karine Bourgeois CSOKV
Kilian von Seldeneck CFOPR
Peter Ruile VP, Head of BD&L Pharma
Investors
Companies like 4TEEN4 Pharmaceuticals
SSEISMIC PharmaceuticalsSeed · Mar 2026
KKinaset Therapeutics$103M Series B+ · Jan 2026
NNeulife$1M Seed · Nov 2025
PPhlox TherapeuticsSeed · Dec 2024AAllStripes$50M Series B+ · Aug 2021
FFelix$1.7M Pre Seed · Apr 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/4teen4-pharmaceuticals-gmbh (get a free API key).